Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

[Trends in urology].

Matieu Uffer1, Yves Chollet, Céclie Cardinaux

  • 1Service d'urologie, CHUV, Lausanne. Matieu.Uffer@chuv.ch

Revue Medicale Suisse
|March 4, 2008
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Correction: Cloître et al. Spatial Distribution of Recurrence and Long-Term Toxicity Following Dose Escalation to the Dominant Intra-Prostatic Nodule for Intermediate-High-Risk Prostate Cancer: Insights from a Phase I/II Study. <i>Cancers</i> 2024, <i>16</i>, 2097.

Cancers·2025
Same author

The role of preoperative immunonutrition on morbidity and immune response after cystectomy: protocol of a multicenter randomized controlled trial (INCyst Trial).

Trials·2024
Same author

Spatial Distribution of Recurrence and Long-Term Toxicity Following Dose Escalation to the Dominant Intra-Prostatic Nodule for Intermediate-High-Risk Prostate Cancer: Insights from a Phase I/II Study.

Cancers·2024
Same author

[Current Trends in the Implantation of the Touch Prosthesis at the Thumb Carpometacarpal Joint: Results of the 1st German-Speaking User Meeting].

Handchirurgie, Mikrochirurgie, plastische Chirurgie : Organ der Deutschsprachigen Arbeitsgemeinschaft fur Handchirurgie : Organ der Deutschsprachigen Arbeitsgemeinschaft fur Mikrochirurgie der Peripheren Nerven und Gefasse : Organ der V...·2024
Same author

Intravesical Ty21a treatment of non-muscle invasive bladder cancer induces immune responses that correlate with safety and may be associated to therapy potential.

Journal for immunotherapy of cancer·2023
Same author

Toxicity, quality of life, and PSA control after 50 Gy stereotactic body radiation therapy to the dominant intraprostatic nodule with the use of a rectal spacer: results of a phase I/II study.

The British journal of radiology·2023
Same journal

Revue medicale suisse·2026
Same journal

Revue medicale suisse·2026
Same journal

Revue medicale suisse·2026
Same journal

Revue medicale suisse·2026
Same journal

Revue medicale suisse·2026
Same journal

[Erythema multiforme : target deciphering].

Revue medicale suisse·2026
See all related articles

New treatments show promise for kidney and prostate cancers. Overweight management aids infertility, while minimally invasive surgery and new stents improve kidney procedures. Botulinum toxin is now covered for overactive bladders.

Area of Science:

  • Oncology
  • Urology
  • Reproductive Medicine

Context:

  • Advances in systemic cancer therapies, including angiogenesis inhibitors for kidney cancer.
  • Development of novel biomarkers for enhanced prostate cancer detection and management.
  • Emerging strategies for improving patient quality of life and surgical outcomes in urological conditions.

Purpose:

  • To review recent advancements in the systemic treatment of kidney cancer.
  • To highlight progress in identifying specific and sensitive markers for prostate cancer.
  • To discuss the benefits of intermittent hormone therapy for prostate cancer patients.
  • To explore the role of weight management in addressing infertility.
  • To evaluate the impact of minimally invasive techniques and new stent technology on kidney surgery.
  • To report on the insurance coverage of botulinum toxin for hyperactive bladder.

Related Experiment Videos

Summary:

  • Systemic treatments targeting angiogenesis show promise for kidney cancer.
  • New markers are being developed for more accurate prostate cancer detection.
  • Intermittent hormone therapy enhances the quality of life for prostate cancer patients.
  • Weight control improves fertility outcomes.
  • Minimally invasive kidney surgery with smaller instruments reduces morbidity.
  • Novel stents decrease reobstruction rates.
  • Botulinum toxin is now a covered treatment for hyperactive bladder.

Impact:

  • Potential for improved cancer treatment efficacy and patient outcomes.
  • Enhanced diagnostic capabilities for prostate cancer.
  • Better quality of life for patients undergoing hormone therapy.
  • Increased success rates for infertility treatments.
  • Reduced complications and faster recovery times for kidney surgery patients.
  • Improved long-term patency rates for stented procedures.
  • Wider accessibility to effective treatment for overactive bladder symptoms.